INmune Bio Inc. with ticker code (INMB) have now 4 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 32 and 15 calculating the mean target price we have 26. With the stocks previous close at 19.99 this would imply there is a potential upside of 30.1%. There is a 50 day moving average of 20.16 and the 200 day MA is 12.13. The market cap for the company is $274m. Visit the company website at: http://www.inmunebio.com
INmune Bio, a clinical-stage immunotherapy company, focuses on reprogramming the patient’s innate immune system to treat cancer Alzheimer’s disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer’s disease; and LivNate to treat patients with non-alcoholic steatohepatitis. The company has license agreements with Xencor; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio was founded in 2015 and is headquartered in La Jolla, California.